Erastin: Precise Ferroptosis Inducer for Cancer Biology and Oxidative Stress Assays

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that induces ferroptosis—an iron-dependent, non-apoptotic form of cell death—by targeting tumor cells with RAS or BRAF mutations and disrupting redox homeostasis via inhibition of system Xc⁻ and modulation of VDAC channels (Fan et al., 2024). Its solubility profile (≥10.92 mg/mL in DMSO, insoluble in water/ethanol) and requirement for -20°C storage ensure experimental reproducibility. Erastin's ability to induce high levels of reactive oxygen species (ROS) distinguishes it mechanistically from apoptosis inducers. Experimental evidence demonstrates its efficacy across multiple tumor cell lines, especially those with oncogenic RAS/RAF pathway mutations (Fan et al., 2024). Erastin, supplied by APExBIO, is integral for research on ferroptosis, redox biology, and novel cancer therapeutics (APExBIO Product Page).

Biological Rationale

Ferroptosis is a regulated form of cell death characterized by iron-dependent accumulation of lipid peroxides, distinct from apoptosis or necrosis (Fan et al., 2024). This process is highly relevant in oncology because many tumor cells, especially those with activating RAS or BRAF mutations, show elevated susceptibility to ferroptosis (see strategic overview). Unlike apoptotic cell death, ferroptosis is not mediated by caspases and is resistant to conventional apoptosis inhibitors. Erastin exploits these vulnerabilities by increasing intracellular ROS and targeting cellular antioxidant defense mechanisms. The clinical importance of ferroptosis includes potential applications in overcoming drug resistance and targeting therapy-refractory tumor populations (Erastin overview).

Mechanism of Action of Erastin

Erastin induces ferroptosis by two primary mechanisms:

• Inhibition of the cystine/glutamate antiporter (system Xc⁻): Erastin blocks cystine uptake, depleting intracellular glutathione, a key antioxidant. This impairs the activity of glutathione peroxidase 4 (GPX4), increasing susceptibility to lipid peroxidation (Fan et al., 2024).
• Modulation of VDAC2/3 channels: Erastin interacts with voltage-dependent anion channels on the mitochondrial membrane, raising mitochondrial ROS production and promoting oxidative damage (Fan et al., 2024, Fig. 1).

This dual action triggers iron-dependent, non-apoptotic, caspase-independent cell death. Notably, Erastin is highly selective for tumor cells with RAS or BRAF pathway mutations, which have heightened baseline oxidative stress and are less able to compensate for further redox disruption. The compound is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with mild warming (APExBIO).

Evidence & Benchmarks

• Erastin induces ferroptosis in RAS- and BRAF-mutant tumor cells, including HT-1080 fibrosarcoma, HEK293T, HeLa, HepG2, RKO, and PC3 cell lines (Fan et al., 2024, https://doi.org/10.1007/s12672-024-00928-y).
• BRD4 inhibitors (e.g., JQ-1, I-BET-762) synergistically enhance Erastin-induced ferroptosis by promoting ROS accumulation and downregulating FSP1 in diverse cell types (Fan et al., 2024, https://doi.org/10.1007/s12672-024-00928-y).
• Optimal in vitro conditions: Erastin at 10–20 μM for 24–48 hours yields robust cell death and ROS elevation in engineered tumor cells (Fan et al., 2024, Table 1, https://doi.org/10.1007/s12672-024-00928-y).
• Erastin’s effect is caspase-independent and resistant to apoptosis inhibitors, confirming its unique mechanism (Fan et al., 2024, https://doi.org/10.1007/s12672-024-00928-y).
• Storage at -20°C is necessary for compound stability; Erastin solutions are unstable for long-term storage and must be freshly prepared (APExBIO, https://www.apexbt.com/erastin.html).

This article extends previous summaries such as this overview by providing recent peer-reviewed benchmarks and mechanistic synergy data with BRD4 inhibitors, clarifying distinct use-cases and best practices.

Applications, Limits & Misconceptions

Research Applications:

• Ferroptosis pathway elucidation in cancer biology and redox research.
• Screening for compounds that modulate iron-dependent, non-apoptotic cell death.
• Modeling therapy resistance and synthetic lethality in RAS/BRAF-mutant cancers.
• Oxidative stress assays using genetically engineered human tumor cells.

Limits:

• Erastin is ineffective in cell lines lacking functional iron uptake or with inactivated ferroptosis machinery (e.g., overexpression of FSP1 or GPX4).
• It does not induce apoptosis; its effects are dependent on iron availability and ROS metabolism.
• Long-term Erastin solutions are not stable; always prepare fresh aliquots before experiments.

Interlink: For protocol optimization and troubleshooting, see Optimizing Ferroptosis Assays with Erastin (SKU B1524), which focuses on workflow best practices and is complemented here with the latest mechanistic and synergy data.

Common Pitfalls or Misconceptions

• Assuming Erastin induces apoptosis: its action is strictly non-apoptotic and caspase-independent.
• Using Erastin in iron-deficient media: ferroptosis requires bioavailable Fe²⁺ for lipid peroxidation.
• Expecting efficacy in cells with high FSP1/GPX4 expression: these factors confer resistance to Erastin-induced ferroptosis.
• Storing Erastin solutions long-term: only the solid should be stored at -20°C; solutions must be freshly prepared.
• Employing water or ethanol as solvents: Erastin is only soluble at experimental concentrations in DMSO.

Workflow Integration & Parameters

For reproducible ferroptosis induction, use Erastin (SKU B1524, APExBIO) dissolved in DMSO at ≥10.92 mg/mL, warming gently if needed (APExBIO). Typical dosing is 10 μM for 24 hours in tumor cell lines, with controls for iron chelation and apoptosis inhibition to validate specificity (Fan et al., 2024). For co-treatment studies, combine with BRD4 inhibitors such as JQ-1 (1 μM) or I-BET-762 (2 μM) to enhance ROS-driven cell death. Ensure all culture media contain sufficient iron and avoid antioxidant-rich supplements. For detailed workflow strategies, compare with this protocol guide, noting this article's additional coverage of synergy and resistance mechanisms.

Conclusion & Outlook

Erastin is a benchmark tool for dissecting ferroptosis and oxidative stress in cancer biology. Its dual targeting of cystine transport (system Xc⁻) and VDAC channels enables selective, robust induction of non-apoptotic cell death in RAS/BRAF-mutant tumor models. Recent evidence highlights combinatorial strategies (e.g., with BRD4 inhibitors) to further sensitize resistant cancer subtypes, supporting its use in preclinical drug discovery and translational research. For detailed product specifications and ordering, visit the Erastin product page at APExBIO.